The most advanced candidate vaccine for malaria has cleared another major hurdle and is now ready for its last and biggest test: a phase Ⅲ trial of 12,000 to 16,000 children at 11 locations in seven African countries. Two new studies published this week by The New England Journal of Medicine-and presented, to considerable excitement, at a meeting~* here on Monday-confirm that the vaccine works and is safe, and, perhaps most important, they show it can be given along with a series of other vaccines that many babies in the developing world receive shortly after birth.
展开▼
